{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T04:00:49Z","timestamp":1730174449332,"version":"3.28.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejpb.2024.114426","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:02:32Z","timestamp":1722045752000},"page":"114426","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dissimilar ferric derisomaltose formulations \u2013 In vitro comparisons between an originator and its intended similars"],"prefix":"10.1016","volume":"203","author":[{"given":"Peter","family":"Langguth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Tulpule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Auerbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114426_b0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/nyas.13347","article-title":"Equivalence of complex drug products: advances in and challenges for current regulatory frameworks","volume":"1407","author":"Hussaarts","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejpb.2024.114426_b0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2015.04.010","article-title":"The similarity question for biologicals and non-biological complex drugs","volume":"76","author":"Crommelin","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 2","key":"10.1016\/j.ejpb.2024.114426_b0015","first-page":"S93","article-title":"Structure, chemistry, and pharmacokinetics of intravenous iron agents","volume":"15","author":"Danielson","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejpb.2024.114426_b0020","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidalproducts-developed_en.pdf, 2015 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejps.2018.11.019","article-title":"Nanomedicines: the magic bullets reaching their target?","volume":"128","author":"Fl\u00fchmann","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ejpb.2024.114426_b0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpba.2013.08.005","article-title":"Structural characterization of iron oxide\/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD)","volume":"86","author":"F\u00fctterer","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ejpb.2024.114426_b0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2018.06.024","article-title":"Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?","volume":"131","author":"M\u00fchlebach","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejpb.2024.114426_b0040","series-title":"Non-Biological Complex Drugs. The Science and the Regulatory Landscape. Vol 20: AAPS Advances in the Pharmaceutical Sciences Series","first-page":"149","article-title":"Iron carbohydrate complexes: characteristics and regulatory challenges","author":"M\u00fchlebach","year":"2015"},{"key":"10.1016\/j.ejpb.2024.114426_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07328303.2023.2272892","article-title":"A comprehensive study of intravenous iron-carbohydrate nanomedicines: from synthesis methodology to physicochemical and pharmaceutical characterization","volume":"42","author":"Tabasi","year":"2023","journal-title":"J Carbohydr Chem"},{"key":"10.1016\/j.ejpb.2024.114426_b0050","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3390\/ijms23042140","article-title":"Criticality of surface characteristics of intravenous iron-carbohydrate nanoparticle complexes: implications for pharmacokinetics and pharmacodynamics","volume":"23","author":"Funk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejpb.2024.114426_b0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer\u00ae), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2024.114426_b0060","unstructured":"European Medicines Agency (EMA), ICH guideline Q8 (R2) on pharmaceutical development. Step 5, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-considerations-ich-guideline-q8-r2-pharmaceutical-development-step-5_en.pdf, 2017 (accessed July 1, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0065","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: a review of their chemistry and key safety aspects \u2013 hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejpb.2024.114426_b0070","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1111\/bph.13268","article-title":"Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management","volume":"172","author":"Szebeni","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejpb.2024.114426_b0075","first-page":"436","article-title":"Intravenous iron-carbohydrate nanoparticles and their similars. What do we choose?","volume":"17","author":"Mehedinti","year":"2022","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.ejpb.2024.114426_b0080","unstructured":"European Medicines Agency (EMA), Questions and answers on generic medicines, https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-and-answers-generic-medicines_en.pdf, 2012 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0085","unstructured":"US Food and Drug Administration (FDA), Generic drug facts, https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drug-facts, 2021 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0090","first-page":"116","article-title":"Are iron sucrose and iron sucrose similar equivalent? Analytical, experimental and clinical determinations","volume":"2","author":"Rottembourg","year":"2018","journal-title":"Nutri Food Sci J"},{"key":"10.1016\/j.ejpb.2024.114426_b0095","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1093\/ndt\/gfr024","article-title":"Do two intravenous iron sucrose preparations have the same efficacy?","volume":"26","author":"Rottembourg","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejpb.2024.114426_b0100","first-page":"176","article-title":"Differences between original intravenous iron sucrose and iron sucrose similar preparations","volume":"59","author":"Toblli","year":"2009","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejpb.2024.114426_b0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/187152812798889358","article-title":"Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model","volume":"11","author":"Toblli","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.ejpb.2024.114426_b0110","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.2147\/DDDT.S151162","article-title":"Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound","volume":"11","author":"Toblli","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejpb.2024.114426_b0115","unstructured":"US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), ANDA submissions \u2013 content and format. Guidance for industry, https:\/\/www.fda.gov\/media\/128127\/download, 2019 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0120","unstructured":"US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. Guidance for industry. Draft guidance, https:\/\/www.fda.gov\/media\/87219\/download, 2021 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0125","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1208\/s12248-017-0126-0","article-title":"Physicochemical characterization of iron carbohydrate colloid drug products","volume":"19","author":"Zou","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.ejpb.2024.114426_b0130","unstructured":"US Food and Drug Administration (FDA), Draft guidance on ferumoxytol, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Ferumoxytol_ivsol_22180_RC12-12.pdf, 2012 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0135","unstructured":"US Food and Drug Administration (FDA), Draft guidance on iron sucrose, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Iron_sucrose_inj_21135_RV11-13.pdf, 2013 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0140","unstructured":"US Food and Drug Administration (FDA), Draft guidance on sodium ferric gluconate complex, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Sodium_ferric_gluconate_complex_inj_20955_RC06-13.pdf, 2013 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0145","unstructured":"US Food and Drug Administration (FDA), Draft guidance on ferric carboxymaltose, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/FERRIC%20CARBOXYMALTOSE_injection_RLD%20203565_RC04-16.pdf, 2016 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0150","unstructured":"US Food and Drug Administration (FDA), Draft guidance on iron dextran, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Iron%20dextran_injetion_RLD%20017441_RC09-16.pdf, 2016 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0155","unstructured":"US Food and Drug Administration (FDA), Draft guidance on ferric derisomaltose, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_208171.pdf, 2024 (accessed June 27, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2016.03.029","article-title":"Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy","volume":"505","author":"Wu","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejpb.2024.114426_b0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejpb.2024.114426_b0170","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI100478","article-title":"Quantitative aspects of iron deficiency in hypochromic anemia (the parenteral administration of iron)","volume":"11","author":"Heath","year":"1932","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejpb.2024.114426_b0175","unstructured":"AMAG Pharmaceuticals Inc., Feraheme\u00ae (ferumoxytol injection), for intravenous use. Prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022180s025lbl.pdf, June 2022 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0180","doi-asserted-by":"crossref","unstructured":"Vifor Pharma UK Ltd., Ferinject 50 mg iron\/mL dispersion for injection\/infusion. Summary of product characteristics, https:\/\/www.medicines.org.uk\/emc\/product\/5910, January 2024 (accessed April 30 2024).","DOI":"10.1002\/opfl.1955"},{"key":"10.1016\/j.ejpb.2024.114426_b0185","unstructured":"American Regent Inc., Injectafer\u00ae (ferric carboxymaltose injection), for intravenous use. Prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203565s024lbl.pdf, May 2023 (accessed April 30 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0190","unstructured":"Pharmacosmos Therapeutics Inc., Monoferric \u2013 ferric derisomaltose injection, solution. Prescribing information, https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=55859d2d-0456-4fa9-b41f-f535accc97db, February 2022 (accessed April 29, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0195","unstructured":"Pharmacosmos UK Ltd., Ferric derisomaltose Pharmacosmos 100 mg\/ml solution for injection\/infusion. Summary of product characteristics, https:\/\/www.medicines.org.uk\/emc\/product\/5676\/smpc, April 2023 (accessed April 29, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0200","unstructured":"Vifor (International) Inc., Switzerland, Dexferrum\u00ae (IRON DEXTRAN INJECTION, USP), Rx only. Prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/040024s022lbl.pdf, (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0205","unstructured":"Allergan, INFeD\u00ae (iron dextran injection), for intravenous or intramuscular use. Prescribing information, https:\/\/www.rxabbvie.com\/pdf\/infed_pi.pdf, September 2021 (accessed April 29, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0210","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1111\/hdi.12560","article-title":"The available intravenous iron formulations: history, efficacy, and toxicology","volume":"21","author":"Auerbach","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ejpb.2024.114426_b0215","unstructured":"Pharmacosmos UK Ltd., CosmoFer 50mg\/ml solution for infusion and injection. Summary of product characteristics, https:\/\/www.medicines.org.uk\/emc\/medicine\/14139, May 2023 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0220","first-page":"286","article-title":"Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease","volume":"34","author":"Mamula","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.ejpb.2024.114426_b0225","unstructured":"US Food and Drug Administration (FDA), ANDA 206604; ANDA approval letter, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/206604Orig1s000ltr.pdf, 2021 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0230","unstructured":"Sandoz Inc., Ferumoxytol \u2013 ferumoxytol injection. Prescribing information, https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=cf94c7fc-13a0-4ac9-bb85-9c38aa704d35&type=display, June 2022 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0235","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: intravenous iron uses, formulations, administration, and management of reactions","author":"Van Doren","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2024.114426_b0240","first-page":"1","article-title":"Pharmaceutical regulation in 15 European countries review","volume":"18","author":"Panteli","year":"2016","journal-title":"Health Syst Transit"},{"key":"10.1016\/j.ejpb.2024.114426_b0245","unstructured":"US Office of Personnel Management (OPM), Health; Questions and answers, https:\/\/www.opm.gov\/frequently-asked-questions\/insure-faq\/health\/can-i-ask-the-pharmacy-to-substitute-a-generic-drug-for-the-drug-prescribed-by-my-doctor\/, (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0250","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejpb.2024.114426_b0255","unstructured":"Nippon Shinyaku Co. Ltd., Launch of MonoVer\u00ae for I.V. injection 500mg\/1000mg for the treatment of iron deficiency anemia [press release]. 15 March 2023. https:\/\/www.nippon-shinyaku.co.jp\/file\/download.php?file_id=6739 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0260","doi-asserted-by":"crossref","first-page":"18859","DOI":"10.1038\/s41598-022-23581-3","article-title":"Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK","volume":"12","author":"Sinclair","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejpb.2024.114426_b0265","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2024.114426_b0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejpb.2024.114426_b0275","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11096-023-01548-2","article-title":"A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose","volume":"45","author":"Kennedy","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.ejpb.2024.114426_b0280","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.26015","article-title":"Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: the FERWON-IDA\/NEPHRO trials","volume":"96","author":"Wolf","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2024.114426_b0285","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2024.114426_b0290","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"IRONMAN Study Group, Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2024.114426_b0295","first-page":"13","article-title":"Iron isomaltoside 1000: a new high dose option for parenteral iron therapy","volume":"26","author":"Kalra","year":"2012","journal-title":"Port J Nephrol Hypert"},{"key":"10.1016\/j.ejpb.2024.114426_b0300","unstructured":"H. Andreasen, inventor; Pharmacosmos Holding A\/S, assignee. Stable iron oligosaccharide compound. US Patent 10414831.17 September 2019."},{"key":"10.1016\/j.ejpb.2024.114426_b0305","unstructured":"Tata 1mg.com, Rapifer 100 injection, https:\/\/www.1mg.com\/drugs\/rapifer-100mg-injection-622679, 2024 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0310","unstructured":"Bio-Labs (Pvt) Ltd., Pharma Health Division comprehensive list of products, https:\/\/bio-labs.net\/wp-content\/uploads\/2023\/11\/Bio-Labs-Comprehensive-Product-List-17-11-23.pdf, 2023 (accessed April 30, 2024)."},{"key":"10.1016\/j.ejpb.2024.114426_b0315","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.scriptamat.2005.12.029","article-title":"Preparation of \u03b3-Fe2O3 nanoparticles using DC thermal arc-plasma route, their characterization and magnetic properties","volume":"54","author":"Banerjee","year":"2006","journal-title":"Scr Mater"},{"key":"10.1016\/j.ejpb.2024.114426_b0320","unstructured":"V.G. Kirakosyan, A.M. Davinyan, A.V. Ginosyan, L.H. Varderesyan, Development and validation of complexometric titration method for the determination of iron in iron-containing liquid dosage forms registered in the Republic of Armenia, Me\u0434\u0438\u0446\u0438\u043dc\u043aa\u044f \u043day\u043aa Ap\u043ce\u043d\u0438\u0438, 61 (2021) 39-45."},{"key":"10.1016\/j.ejpb.2024.114426_b0325","unstructured":"European Pharmacopoeia, 2.2.3. Potentiometric determination of pH, July 2016."},{"key":"10.1016\/j.ejpb.2024.114426_b0330","unstructured":"European Pharmacopoeia, 2.2.5. Relative density, January 2008."},{"key":"10.1016\/j.ejpb.2024.114426_b0335","unstructured":"The British Pharmacopoeia Commission, British Pharmacopoeia 2017. Vol III, The Stationery Office Limited, London, 2017."},{"key":"10.1016\/j.ejpb.2024.114426_b0340","unstructured":"US Pharmacopeia, Monograph for iron dextran injection, October 2023."},{"key":"10.1016\/j.ejpb.2024.114426_b0345","first-page":"296","article-title":"Safety of intravenous iron formulations: facts and folklore","volume":"12","author":"Auerbach","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.ejpb.2024.114426_b0350","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ajh.24326","article-title":"Is low-molecular weight iron dextran really the most risky iron? \u2013 Unconvincing data from an unconvincing study","volume":"91","author":"DeLoughery","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejpb.2024.114426_b0355","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/ndt\/gfi253","article-title":"Update on adverse drug events associated with parenteral iron","volume":"21","author":"Chertow","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejpb.2024.114426_b0360","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/acs.molpharmaceut.0c00922","article-title":"Evaluation of the physicochemical properties of the iron nanoparticle drug products: brand and generic sodium ferric gluconate","volume":"18","author":"Brandis","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ejpb.2024.114426_b0365","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.iac.2014.04.013","article-title":"Hypersensitivity from intravenous iron products","volume":"34","author":"Bircher","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.ejpb.2024.114426_b0370","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejpb.2024.114426_b0375","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejpb.2023.04.025","article-title":"Putting square pegs in round holes: why traditional pharmacokinetic principles cannot universally be applied to iron-carbohydrate complexes","volume":"188","author":"Barton Alston","year":"2023","journal-title":"Eur J Pharm Biopharm"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:18:42Z","timestamp":1730092722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124002522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":75,"alternative-id":["S0939641124002522"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114426","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissimilar ferric derisomaltose formulations \u2013 In vitro comparisons between an originator and its intended similars","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114426"}}